{'fraction_non_alphanumeric': 0.0343980343980344, 'fraction_numerical': 0.002457002457002457, 'mean_word_length': 5.476190476190476, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The long road: improving outcome in elderly "unfit" AML?

In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.